10 No-Brainer Stocks to Buy Now
Fed Chair Kevin Warsh gave no hint of another rate hike at an IMF event in Bangkok on October 16, and the odds of an October increase fell to roughly 15% on CME FedWatch, according to Benzinga on October...
Astrazeneca Plc (AZN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Gotham Asset Management Joel Greenblatt | 0 | $0 | 0% | |
| 2. | NWI Management Hari Hariharan | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $160.57 | 20 | $3,248.81 | 19,288 | 2026-08-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $185.78 | 11,893 | $2,209,481.54 | 19,262 | 2026-05-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 102,629 | $16,571,505 | 2.12% | |
| 2. | 48,578 | $7,843,891 | 1.17% | |
| 3. | 403 | $65,072 | 0.02% | |
| 4. | 72 | $11,354 | 0.01% | |
| 5. | 6,968 | $1,125 | 0.74% |
News See All
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%.
AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?
AstraZeneca PLC (US) (NYSE:AZN) is on the cusp of unlocking a new growth engine in lung cancer treatment.
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
Becton Dickinson (BDX) Joins Trump Tariff Exemption Scramble with $19B Investment Plan
U.S. medical device company Becton Dickinson ($BDX) has agreed to invest $19 billion in the U.S. over several years, the company announced in a sta...
AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up
AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies' cancer drugs.
Why Is Summit Therapeutics Stock (SMMT) Soaring in Premarket Today, Sept. 29?
Summit Therapeutics ($SMMT) stock is up 22% in Tuesday’s premarket trading. The gain came after AstraZeneca ($AZN) announced a $2 billion equity in...
AstraZeneca (AZN) is Expanding its Oncology Engine. Can New Growth Offset Legacy Pressure?
It was reported on September 25 that the U.S.
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing...
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market?
AstraZeneca PLC (NYSE:AZN) announced on September 11, 2026, that its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression...
Hedge Fund Resource Center